These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20596644)

  • 1. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma.
    Sasaki A; Kamiyama T; Yokoo H; Nakanishi K; Kubota K; Haga H; Matsushita M; Ozaki M; Matsuno Y; Todo S
    Oncol Rep; 2010 Aug; 24(2):537-46. PubMed ID: 20596644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
    Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
    Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis.
    Kim H; Choi GH; Na DC; Ahn EY; Kim GI; Lee JE; Cho JY; Yoo JE; Choi JS; Park YN
    Hepatology; 2011 Nov; 54(5):1707-17. PubMed ID: 22045674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma.
    Chan AW; Tong JH; Chan SL; Lai PB; To KF
    Histopathology; 2014 Jun; 64(7):935-50. PubMed ID: 24506513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis.
    Ma YC; Yang JY; Yan LN
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1007-16. PubMed ID: 23478672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection.
    Yeh CT; Kuo CJ; Lai MW; Chen TC; Lin CY; Yeh TS; Lee WC
    BMC Cancer; 2009 Sep; 9():324. PubMed ID: 19744348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection.
    Sun YF; Xu Y; Yang XR; Guo W; Zhang X; Qiu SJ; Shi RY; Hu B; Zhou J; Fan J
    Hepatology; 2013 Apr; 57(4):1458-68. PubMed ID: 23175471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients.
    Chen YL; Lin PY; Ming YZ; Huang WC; Chen RF; Chen PM; Chu PY
    BMC Cancer; 2017 Jul; 17(1):474. PubMed ID: 28687090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma.
    Guo Z; Li LQ; Jiang JH; Ou C; Zeng LX; Xiang BD
    World J Gastroenterol; 2014 Feb; 20(8):2098-106. PubMed ID: 24616575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer.
    Hashimoto K; Aoyagi K; Isobe T; Kouhuji K; Shirouzu K
    Gastric Cancer; 2014 Jan; 17(1):97-106. PubMed ID: 23558457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological characteristics of 20 cases of hepatocellular carcinoma with bile duct tumor thrombi.
    Yu XH; Xu LB; Liu C; Zhang R; Wang J
    Dig Dis Sci; 2011 Jan; 56(1):252-9. PubMed ID: 20437099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biology and clinical implications of CD133(+) liver cancer stem cells.
    Ma S
    Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients.
    Takahashi S; Kamiyama T; Tomaru U; Ishizu A; Shida T; Osaka M; Sato Y; Saji Y; Ozaki M; Todo S
    Oncol Rep; 2010 Nov; 24(5):1201-12. PubMed ID: 20878111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.
    Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N
    J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
    Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
    Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity.
    Yin S; Li J; Hu C; Chen X; Yao M; Yan M; Jiang G; Ge C; Xie H; Wan D; Yang S; Zheng S; Gu J
    Int J Cancer; 2007 Apr; 120(7):1444-50. PubMed ID: 17205516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma.
    Lingala S; Cui YY; Chen X; Ruebner BH; Qian XF; Zern MA; Wu J
    Exp Mol Pathol; 2010 Aug; 89(1):27-35. PubMed ID: 20511115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma.
    Zhang C; Xu Y; Zhao J; Fan L; Jiang G; Li R; Ling Y; Wu M; Wei L
    Ann Surg Oncol; 2011 Aug; 18(8):2373-80. PubMed ID: 21331808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasion and EMT-associated genes are up-regulated in B viral hepatocellular carcinoma with high expression of CD133-human and cell culture study.
    Na DC; Lee JE; Yoo JE; Oh BK; Choi GH; Park YN
    Exp Mol Pathol; 2011 Feb; 90(1):66-73. PubMed ID: 20969862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma.
    Hagiwara S; Kudo M; Ueshima K; Chung H; Yamaguchi M; Takita M; Haji S; Kimura M; Arao T; Nishio K; Park AM; Munakata H
    J Gastroenterol; 2011 Feb; 46(2):212-21. PubMed ID: 20683621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.